Salofalk · DIN 02112809 · 4 g · Rect suspension-Pk
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Salofalk · DIN 02112809
Manufacturer: Axcan Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2024-06-12 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Suspension · route Rectal · ingredients MESALAZINE 4 G/60G · company Abbvie corporation · schedule Prescription
Salofalk: Formulary list price $10.04 per unit (the source does not state the unit; exact figure $10.0389). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02112809)
Source record
DIN 02112809: Salofalk
Raw flags: sec3=Y
Item: 564000034; group id 672; item number 1676; lccId None; manufacturer id BFI
Source form: Rect Susp-Pk; strength: 4g
Recorded listing: General benefit
Source prices (unrounded): $10.0389; ministry $10.0389
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02112809
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18509
Shortage status: not checked (no credentials)